Ustekinumab Tissue and Serum Levels in Patients With Crohn’s Disease Are Closely Correlated Though Not Consistently Associated With Objective Response After Induction

BACKGROUND: Ustekinumab (UST), which targets p40/interleukin (IL)-23 and IL-12, is an effective treatment for Crohn’s disease (CD). Therapeutic drug monitoring may optimize UST posology. The aim of this study was to investigate UST and IL-23 serum and tissue concentrations in relation to mucosal inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Proietti, Elisa, Pauwels, Renske W M, van der Woude, Christien J, Doukas, Michael, Oudijk, Lindsey, Peppelenbosch, Maikel P, Grohmann, Ursula, Crombag, Marie-Rose B S, de Vries, Annemarie C, Fuhler, Gwenny M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320373/
https://www.ncbi.nlm.nih.gov/pubmed/35917118
http://dx.doi.org/10.1093/ibd/izac169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320373/
https://www.ncbi.nlm.nih.gov/pubmed/35917118
http://dx.doi.org/10.1093/ibd/izac169

Ejemplares similares